Insider · CIK 0001791857
Kyle Jenne
Files at IONS (IONIS PHARMACEUTICALS INC). First filing Apr 17, 2025, latest Apr 17, 2026.
In brief
Kyle Jenne files SEC Form 4 as officer at IONS (IONIS PHARMACEUTICALS INC). Since Apr 17, 2025, Kyle Jenne has reported 0 open-market buys worth $0 and 4 open-market sells worth $3.4M, the latest filed on Apr 17, 2026.
A track record needs three past buys with six months of prices behind them; Kyle Jenne has 0, so none is measured yet.
The newest scored trade: sold $368k of IONS on Apr 16, 2026, filed Apr 17, 2026, scored 35 (weak). In the last 12 months: 0 buys worth $0 and 3 sells worth $3.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IONS: IONIS PHARMACEUTICALS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | IONIS PHARMACEUTICALS INC | $368k 4,902 shares | -17% | +165% from low-13% from high | |
| 40Moderate | IONIS PHARMACEUTICALS INC | $2.8M 37,277 shares | -76% | +197% from low-13% from high | |
| 31Weak | IONIS PHARMACEUTICALS INC | $138k 1,823 shares | -10% | +199% from low-8% from high | |
| 29Weak | IONIS PHARMACEUTICALS INC | $86k 3,016 shares | -21% | +11% from low-34% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 16, 2026 | IONS IONIS PHARMACEUTICALS INC | 4,902 0.00% of outstanding | $370k | Apr 16, 2026 | $3.0M |
| Mar 10, 2026 | IONS IONIS PHARMACEUTICALS INC | 58,253 0.04% of outstanding | $4.4M | Mar 10, 2026 | $139k |
| Jan 16, 2026 | IONS IONIS PHARMACEUTICALS INC | 1,823 0.00% of outstanding | $139k | Jan 16, 2025 | none |
| Apr 16, 2025 | IONS IONIS PHARMACEUTICALS INC | 3,016 0.00% of outstanding | $86k | Apr 16, 2025 | none |
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Common Stock | +12,226 | $0.00 | $0 | 28,615 | Apr 17, 2026 |
| Apr 16, 2026 | IONS IONIS PHARMACEUTICALS INC | SOpen-market sale Common Stock | -4,902 | $75.17 | $368k | 23,713 | Apr 17, 2026 |
| Apr 15, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitderivative | -12,226 | $0.00 | $0 | 74,402 | Apr 17, 2026 |
| Mar 10, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +32,602 | $46.10 | $1.5M | 48,991 | Mar 11, 2026 |
| Mar 10, 2026 | IONS IONIS PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -21,191 | $75.50 | $1.6M | 27,800 | Mar 11, 2026 |
| Mar 10, 2026 | IONS IONIS PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -16,086 | $76.30 | $1.2M | 11,714 | Mar 11, 2026 |
| Mar 10, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +4,675 | $34.69 | $162k | 16,389 | Mar 11, 2026 |
| Mar 10, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -4,675 | $0.00 | $0 | 14,025 | Mar 11, 2026 |
| Mar 10, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -32,602 | $0.00 | $0 | 32,601 | Mar 11, 2026 |
| Jan 15, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Common Stock | +7,013 | $0.00 | $0 | 18,212 | Jan 20, 2026 |
| Jan 16, 2026 | IONS IONIS PHARMACEUTICALS INC | SOpen-market sale Common Stock | -1,823 | $75.96 | $138k | 16,389 | Jan 20, 2026 |
| Jan 15, 2026 | IONS IONIS PHARMACEUTICALS INC | AGrant or award Performance Restricted Stock Unitsderivative | +25,800 | $0.00 | $0 | 44,500 | Jan 20, 2026 |
| Jan 15, 2026 | IONS IONIS PHARMACEUTICALS INC | AGrant or award Restricted Stock Unitderivative | +9,675 | $0.00 | $0 | 37,725 | Jan 20, 2026 |
| Jan 15, 2026 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitderivative | -7,013 | $0.00 | $0 | 29,664 | Jan 20, 2026 |
| Jan 2, 2026 | IONS IONIS PHARMACEUTICALS INC | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +19,350 | $0.00 | $0 | 19,350 | Jan 6, 2026 |
| Apr 15, 2025 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Common Stock | +12,226 | $0.00 | $0 | 14,215 | Apr 17, 2025 |
| Apr 16, 2025 | IONS IONIS PHARMACEUTICALS INC | SOpen-market sale Common Stock | -3,016 | $28.36 | $86k | 11,199 | Apr 17, 2025 |
| Apr 15, 2025 | IONS IONIS PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitderivative | -12,226 | $0.00 | $0 | 36,677 | Apr 17, 2025 |
| Jan 15, 2025 | IONS IONIS PHARMACEUTICALS INC | AGrant or award Performance Restricted Stock Unitsderivative | +18,700 | $0.00 | $0 | 18,700 | Jan 17, 2025 |
| Jan 15, 2025 | IONS IONIS PHARMACEUTICALS INC | AGrant or award Restricted Stock Unitderivative | +28,050 | $0.00 | $0 | 28,050 | Jan 17, 2025 |
| Jan 2, 2025 | IONS IONIS PHARMACEUTICALS INC | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +18,700 | $0.00 | $0 | 18,700 | Jan 6, 2025 |
Questions about Kyle Jenne
Answered from the filings on this page, as of the latest one.
Is Kyle Jenne buying or selling?
In the last 12 months Kyle Jenne reported 0 open-market buys worth $0 and 3 open-market sells worth $3.3M on SEC Form 4; the latest was sold $368k of IONS on Apr 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Kyle Jenne's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kyle Jenne has 0.
Where does Kyle Jenne file Form 4?
Kyle Jenne has filed Form 4 at IONS (IONIS PHARMACEUTICALS INC) as EVP, Chf GL Pdt Str Ofcr. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.